(Total Views: 719)
Posted On: 12/28/2023 4:49:06 PM
Post# of 154896
Anybody notice CYTK's 25 point gap up on good Phase 3 clinical trial results?
(It's for a heart drug, for a relatively small group of people, but when approved can be used off-label by millions of people. It's an improved drug similar to their current drug mavacamten.)
That's what can happen. Similar to the late lamented DNDN which gapped up from 7 to 20.
https://bigcharts.marketwatch.com/advchart/fr...p;state=11
(It's for a heart drug, for a relatively small group of people, but when approved can be used off-label by millions of people. It's an improved drug similar to their current drug mavacamten.)
That's what can happen. Similar to the late lamented DNDN which gapped up from 7 to 20.
https://bigcharts.marketwatch.com/advchart/fr...p;state=11
(3)
(0)
